AIM ImmunoTech Inc (AIM)
0.2101
0.00 (0.00%)
USD |
NYAM |
Nov 22, 16:00
0.21
0.00 (0.00%)
After-Hours: 20:00
AIM ImmunoTech Cash from Financing (Quarterly): 0.137M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.137M |
| June 30, 2024 | 2.441M |
| March 31, 2024 | 2.829M |
| December 31, 2023 | 0.147M |
| September 30, 2023 | 0.233M |
| June 30, 2023 | 0.005M |
| March 31, 2023 | 0.10M |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.025M |
| June 30, 2022 | 0.055M |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.125M |
| September 30, 2021 | 0.03M |
| June 30, 2021 | -4.761M |
| March 31, 2021 | 12.79M |
| December 31, 2020 | 3.041M |
| September 30, 2020 | 17.16M |
| June 30, 2020 | 10.68M |
| March 31, 2020 | 25.69M |
| December 31, 2019 | -0.568M |
| September 30, 2019 | 11.43M |
| June 30, 2019 | 0.87M |
| March 31, 2019 | 4.65M |
| December 31, 2018 | 0.181M |
| September 30, 2018 | 2.846M |
| Date | Value |
|---|---|
| June 30, 2018 | 2.357M |
| March 31, 2018 | 4.051M |
| December 31, 2017 | 0.582M |
| September 30, 2017 | 1.001M |
| June 30, 2017 | 1.757M |
| March 31, 2017 | 0.875M |
| December 31, 2016 | 0.064M |
| September 30, 2016 | 4.531M |
| June 30, 2016 | 0.161M |
| March 31, 2016 | 0.001M |
| December 31, 2015 | -0.001M |
| September 30, 2015 | 0.383M |
| June 30, 2015 | 4.043M |
| March 31, 2015 | 5.235M |
| December 31, 2014 | 3.046M |
| September 30, 2014 | 1.299M |
| June 30, 2014 | 2.066M |
| March 31, 2014 | 6.374M |
| December 31, 2013 | -6.811M |
| September 30, 2013 | -0.007M |
| June 30, 2013 | -0.016M |
| March 31, 2013 | -0.013M |
| December 31, 2012 | 15.01M |
| September 30, 2012 | 10.68M |
| June 30, 2012 | 2.046M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-4.761M
Minimum
Jun 2021
25.69M
Maximum
Mar 2020
3.508M
Average
0.131M
Median
Cash from Financing (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 0.628M |
| Protalix BioTherapeutics Inc | -20.42M |
| Electromed Inc | -4.467M |
| Xtant Medical Holdings Inc | 5.314M |
| Armata Pharmaceuticals Inc | -0.061M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.11M |
| Cash from Investing (Quarterly) | 0.334M |
| Free Cash Flow | -21.33M |
| Free Cash Flow Per Share (Quarterly) | -0.0567 |
| Free Cash Flow to Equity (Quarterly) | -3.363M |
| Free Cash Flow Yield | -194.4% |